Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma.

Literature DB >> 25905905

Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma.

Roy E Strowd¹, Inas A Abuali, Stuart A Grossman.

Abstract

Indolent CNS lymphomas (CNSLs) are rare and no guidelines exist for management. Recent literature highlights the potential for safe and tolerable intrathecal (IT) delivery of rituximab, a large anti-CD20 monoclonal antibody, for aggressive CNSL. We report a patient with relapsed indolent CNSL who failed systemic rituximab and could not tolerate IT chemotherapies, but had an objective response of 6 months duration to IT rituximab.

Entities: Chemical Disease Gene Species

Keywords: CNS lymphoma; indolent lymphoma; intrathecal rituximab; low-grade lymphoma

Mesh：

Substances：

Year: 2015 PMID： 25905905 PMCID： PMC4778415 DOI： 10.2217/cns.15.3

Source DB: PubMed Journal: CNS Oncol ISSN： 2045-0907

15 in total

1. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab.

Authors: Holger Schulz; Hendrik Pels; Ingo Schmidt-Wolf; Ulrich Zeelen; Ulrich Germing; Andreas Engert
Journal: Haematologica Date: 2004-06 Impact factor: 9.941

Review 2. Improving outcomes for patients with diffuse large B-cell lymphoma.

Authors: Christopher R Flowers; Rajni Sinha; Julie M Vose
Journal: CA Cancer J Clin Date: 2010-10-28 Impact factor: 508.702

3. Biclonal low grade B-cell lymphoma confirmed by both flow cytometry and karyotypic analysis, in spite of a normal kappa/lambda Ig light chain ratio.

Authors: J P Delville; P Heimann; H El Housni; M Boutriaux; A Jeronnez; M Remmelink; J Lasudry; O Pradier; A Kentos
Journal: Am J Hematol Date: 2007-06 Impact factor: 10.047

4. Rituximab monotherapy for patients with recurrent primary CNS lymphoma.

Authors: T T Batchelor; S A Grossman; T Mikkelsen; X Ye; S Desideri; G J Lesser
Journal: Neurology Date: 2011-03-08 Impact factor: 9.910

5. Low-grade primary central nervous system lymphoma in immunocompetent patients.

Authors: Kristoph Jahnke; Eckhard Thiel; Andreas Schilling; Ulrich Herrlinger; Michael Weller; Sarah E Coupland; Ulrich Krümpelmann; Harald Stein; Agnieszka Korfel
Journal: Br J Haematol Date: 2005-03 Impact factor: 6.998

6. Detection of free immunoglobulin light chains in cerebrospinal fluids of patients with central nervous system lymphomas.

Authors: Roland Schroers; Alexander Baraniskin; Christoph Heute; Jan Kuhnhenn; Andriy Alekseyev; Wolff Schmiegel; Uwe Schlegel; Hendrik-Johannes Pels
Journal: Eur J Haematol Date: 2010-05-26 Impact factor: 2.997

7. High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma.

Authors: Marc C Chamberlain; Sandra K Johnston
Journal: Neuro Oncol Date: 2010-02-08 Impact factor: 12.300

8. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma.

Authors: James L Rubenstein; Jane Fridlyand; Lauren Abrey; Arthur Shen; Jon Karch; Endi Wang; Samar Issa; Lloyd Damon; Michael Prados; Michael McDermott; Joan O'Brien; Chris Haqq; Marc Shuman
Journal: J Clin Oncol Date: 2007-02-20 Impact factor: 44.544

Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma.

1. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab.

Review 2. Improving outcomes for patients with diffuse large B-cell lymphoma.

3. Biclonal low grade B-cell lymphoma confirmed by both flow cytometry and karyotypic analysis, in spite of a normal kappa/lambda Ig light chain ratio.

4. Rituximab monotherapy for patients with recurrent primary CNS lymphoma.

5. Low-grade primary central nervous system lymphoma in immunocompetent patients.

6. Detection of free immunoglobulin light chains in cerebrospinal fluids of patients with central nervous system lymphomas.

7. High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma.

8. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma.

9. Bing-Neel syndrome: a case report and systematic review of clinical manifestations, diagnosis, and treatment options.

Review 10. Aiming at a curative strategy for follicular lymphoma.

1. Characteristics and outcomes of non-Hodgkin's lymphoma patients with leptomeningeal metastases.

Review 2. Primary central nervous system lymphoma.